SIGA Technologies Inc.

Welcome to the SIGA Business Update call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results that differ from the forward-looking statements. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or changed circumstances after this call. For a discussion of factors that would cause results to differ, please see the company's filings with the Securities and Exchange Commission, including, without limitation, the company's annual report on Form 10-K for the year ended December 31, 2023. and its subsequent reports on Form 10-Q and Form 8-K. I will now hand the call over to Zem Nguyen, CEO of SEGA. Please go ahead.

Good afternoon, everyone, and thank you for joining today's call and review of our business results for the fourth quarter and full year of 2023. I am joined by Dan Luckshire, our Chief Financial Officer, and we're pleased to have this opportunity to provide an update to our shareholders. After the update, we'll be happy to answer any of your questions. I'd like to begin by recognizing the work and contributions of Phil Gomez, who served as CIGA's CEO for the seven years. Phil was instrumental in transforming our company into a more commercial organization, with sales in over 25 countries and securing key regulatory approvals for our CPOX franchise. On behalf of our team, I want to thank Phil for his many contributions to making SIGA the strong company it is today. On a personal note, I'm excited to join SIGA and take on the role of CEO. Having spent nearly three decades focused on addressing unmet needs in healthcare, I look forward to building on SIGA's success and driving greater growth for the benefit of our patients, customers, and shareholders. I have a deep-seated passion for scientific advancement and innovation, as well as an extensive experience leading successful multi-billion dollar commercial organizations. I'm extremely excited to leverage this experience to help fulfill SIGA's potential and have our essential therapies available worldwide. Although this is only my sixth week with the company, I'm pleased to share my belief in SIGA's bright future. This belief has been grounded for the following. First, SIGA has strong business fundamentals. It is a highly profitable company with a management team that has deep expertise in commercial activities, antiviral R&D, and government relations. And the company has built and maintains a fully integrated U.S.-based operational supply chain. This is a distinguishing asset for our customers. Second, TPox is a foundational product franchise that has a track record of securing multi-year government contracts, which have totaled over $1 billion in the past 10 years. Again, this is a point of distinction and speaks to the significant value of TPOC. Third, FIGA has achieved best-in-class financial performance. Our average annual pre-tax operating income over the past four years has been $75 million. These results have been achieved while maintaining a strong balance sheet. Fourth, FIGA has attractive growth opportunities. Let me just mention a few. In the near term, CEGA has the potential to expand the indications of TPOCs to include post-exposure prophylaxis, which we like to call PEP, and MPOCs. I'll provide an update on these programs a little later in these remarks. Also in the near term, CEGA has the opportunity to expand geographically and work with governments across the world to fully embrace stockpiling, and preparedness for a full range of orthopoxvirus risks. We want to ensure governments have a modernized view of the risks and the tools for protection against orthopoxviruses. And thinking more broadly, SIGA has strong antiviral and government procurement capabilities. We believe these capabilities are best in class, that we can leverage to move into complementary therapeutic areas with similar points of patient care. Importantly, all of this has reinforced TPOC's leadership among infectious disease countermeasures. TIGA's expertise and experience in commercial execution, R&D innovation, and government contracting enables us to support the highest level of public and individual safety. As a result of these four critical factors, I believe SIGA is well positioned for further innovation, strong business performance, and attractive value creation for our shareholders. Now turning to our financial results, I am very pleased to report that we finished the year strong. Full year 2023 product revenues of $131 billion are the highest amounts achieved over the past five years. This reflects a 51% increase over 2022. Approximately $116 million of the full-year product revenues were achieved in the fourth quarter, coming from a diversity of sources, including the U.S. Strategic National Stockpile, or the SMS, the U.S. Department of Defense, and five international governments. Pre-tax operating income was approximately $84 million in 2023, a 96% increase over 2022. This is a testament to the strength of the SIGA team, the value of our franchise, and the resilience of our company. Dan will provide more details on these results shortly. Additionally, in 2023, we spent 43 million on capital management through a combination of special cash dividend and share buyback. And I'm pleased to announce that our board of directors has declared a special dividend of 60 cents per share to be paid in April. This represents a 33% increase over the special dividend we paid in June of 2023. This demonstrates the financial strength of our company and the confidence the board and the management team have in our future. Our proven track record, coupled with the potential of a new long-term contract with S&S, provides both a compelling and attractive backdrop for our company in both the short and longer term. Looking forward, we plan on continuing to invest to grow our business, while maintaining a balanced and disciplined capital allocation approach with the goal of delivering strong long-term revenues and earnings growth and creating value for our shareholders. And now, I would like to talk about PEP and MPOPS programs. With regard to PEP, I will start by recapping what was reported on the last investor call. Based on the studies and trials that have been conducted, we believe TPOC benefits patients in a prophylactic situation. The FDA has not asked for any additional studies to prove the efficacy of TPOCs for pets, but has asked for extended safety data in humans for treatment for 28 days. We have completed this requirement, and the data is consistent with prior safety studies. It is important to emphasize the clinical trial results do not show any drug-related serious adverse events, consistent with TPOC's existing strong safety profile. In addition to the safety trial, we have completed a genio-TPOC immunogenicity trial solely to evaluate if TPOC has an impact on vaccine immune response. Because in the event of an outbreak, TPOX treatment would likely to be used in combination with a smallpox vaccine. In the preliminary analysis of the data from the immunogenicity trial, consistent with what we expected, the results did not show a meaningful difference between the immunogenicity of those who received the JYNNEOS vaccine while on placebo compared to those that received the JYNNEOS vaccine while on TPOX. However, as mentioned previously, the results indicated that the number of volunteers who had measurable immune response to the Junios vaccine in both the placebo and TPOX groups was lower than expected. Given this result, the data deemed difficult to assess for the non-inferior statistical determination, which was necessary for the primary endpoint as originally planned in the study. On the last investor call, we also reported that a subset of the GINEAS and TPOC samples from the immunogenicity trial were sent to our colleagues at the CDC who performed their validated print analysis on them. These samples showed the expected immune responses. As such, we are now working on getting the entire set of the samples reanalyzed given the challenges associated with the prior analysis conducted our CRO vendor. We believe these preliminary CDC analyses provide a potential path forward despite the unexpected nature of the prior results. As such, in parallel, we are working towards a supplemental NDA submission within the next 12 months. We are grateful to our colleagues at the CDC for this collaboration and efficient path forward. We believe this is the best course of action in terms of getting timely data from the immunogenicity trial, and the FDA agrees, as they have been briefed on our plan and have not voiced any objections. As a final comment on the PEP program, I want to emphasize that the immunogenicity analysis are not about the efficacy or safety of TPOCs. nor are they about TPOX impact on those individuals who are showing an immune response. Rather, the relevance of the immunogenicity study is that in the case of an orthopox virus epidemic, be it MPOX or smallpox, use of TPOX with a vaccine for pets will be important to reduce the morbidity and mortality of the population without sacrificing patient safety. Now I would like to shift gears and provide a quick update on the current MPOCS trials involving TPOCS, which include four randomized controlled trials, as well as multiple observational studies. These studies continue to enroll patients and collect data. To provide some specific data points, In Africa, as of February, the NIAID PALMS trial being conducted in the DRC has enrolled approximately 425 patients, a large increase from the 314 patients noted in our last call. In the NIAID STOMP trial, as of February, there were 267 patients, which is also a substantial increase from the 157 patients noted in our last call. These increases in patient numbers demonstrate that the case counts continue to accumulate, especially in Africa. Importantly, they also provide a glimpse, some would say a warning, into the overall global health risk posed by orthopoxviruses. As such, we are working closely with the NIH and other health agencies on randomized clinical trials to demonstrate whether TPOX is safe and effective for treating MPOX in Africa, the U.S., and other parts of the world to achieve the best possible outcome for MPOX patients from a public health perspective. I would like to remind, however, TPOX is approved for smallpox, MPOX, cowpox, and bifidinia complications in Europe and in the U.K. At this point, I would like to turn the call over to Dan for the financial update.

Thanks, Jen.